A T-rojan horse strategy for cancer immunotherapy

Sci Immunol. 2021 May 7;6(59):eabj3098. doi: 10.1126/sciimmunol.abj3098.

Abstract

CDK4/6 inhibitor-treated breast cancer cells recruit T cells via metabolic stress-induced chemokines.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Breast Neoplasms / immunology
  • Breast Neoplasms / therapy*
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Chemokines / immunology
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
  • Female
  • Humans
  • Immunotherapy*
  • Mice
  • Oxidative Stress
  • Piperazines / pharmacology*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyridines / pharmacology*
  • T-Lymphocytes* / drug effects
  • T-Lymphocytes* / immunology
  • T-Lymphocytes* / transplantation

Substances

  • Antineoplastic Agents
  • Chemokines
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridines
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • palbociclib